AKEBIA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
AKEBIA THERAPEUTICS, INC. (AKBA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 1.02 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 490.89K shares, a 6.52% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 529.06K shares, a 8.87% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 498.33K shares, a 19267.78% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 20.99K shares, a 74.94% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.62M shares, a 145.15% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 662.84K shares, a 70.10% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 2.22M shares.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2017 was 528.95K shares, a 36.05% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 490.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 1.02M shares 10-Q · filed 2026-08-05 | 1.52M shares derived: sum of 3 quarters · filed 2026-08-05 | 1.54M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 529.06K shares 10-Q · filed 2026-05-07 | 1.03M shares derived: sum of 2 quarters · filed 2026-05-07 | 1.05M shares derived: sum of 3 quarters · filed 2026-05-07 | 1.57M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 498.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 519.33K shares derived: sum of 2 quarters · filed 2026-02-26 | 1.04M shares derived: sum of 3 quarters · filed 2026-02-26 | 1.62M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 20.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 546.09K shares derived: sum of 2 quarters · filed 2025-11-10 | 1.13M shares 10-Q · filed 2025-11-10 | 1.13M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 525.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 1.11M shares 10-Q · filed 2025-08-07 | 1.11M shares derived: sum of 3 quarters · filed 2025-08-07 | 1.12M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 580.53K shares 10-Q · filed 2025-05-08 | 583.10K shares derived: sum of 2 quarters · filed 2025-05-08 | 595.10K shares derived: sum of 3 quarters · filed 2025-05-08 | 1.03M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 2.57K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 14.57K shares derived: sum of 2 quarters · filed 2025-03-13 | 444.67K shares derived: sum of 3 quarters · filed 2025-03-13 | 662.84K shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 12.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 442.10K shares derived: sum of 2 quarters · filed 2024-11-07 | 660.27K shares 10-Q · filed 2024-11-07 | 1.58M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 430.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 648.27K shares 10-Q · filed 2024-08-08 | 1.57M shares derived: sum of 3 quarters · filed 2024-08-08 | |
| 2024-03-31 | 218.18K shares 10-Q · filed 2024-05-09 | 1.14M shares derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2023-12-31 | 917.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 2.22M shares 10-K · filed 2024-03-14 | ||
| 2023-09-30 | 1.30M shares 10-Q · filed 2023-11-08 | |||
| 2017-12-31 | 528.95K shares 10-K · filed 2018-03-12 | |||
| 2016-12-31 | 388.78K shares 10-K · filed 2017-03-06 | |||
| 2015-12-31 | 93.09K shares 10-K · filed 2016-03-14 | |||
| 2014-12-31 | 123.47K shares 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |